Impact of postprandial glycaemia on health and prevention of disease.

E.E. Blaak, J.M. Antoine, D. Benton, I. Bjorck, L. Bozzetto, F. Brouns, M. Diamant, L. Dye, T. Hulshof, J.J. Holst, D. J. Lamport, M. Laville, C. L. Lawton, A. Meheust*, A. Nilson, S. Normand, A. A. Rivellese, S. Theis, S. S. Torekov, S. Vinoy

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Postprandial glucose, together with related hyperinsulinemia and lipidaemia, has been implicated in the development of chronic metabolic diseases like obesity, type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). In this review, available evidence is discussed on postprandial glucose in relation to body weight control, the development of oxidative stress, T2DM, and CVD and in maintaining optimal exercise and cognitive performance. There is mechanistic evidence linking postprandial glycaemia or glycaemic variability to the development of these conditions or in the impairment in cognitive and exercise performance. Nevertheless, postprandial glycaemia is interrelated with many other (risk) factors as well as to fasting glucose. In many studies, meal-related glycaemic response is not sufficiently characterized, or the methodology with respect to the description of food or meal composition, or the duration of the measurement of postprandial glycaemia is limited. It is evident that more randomized controlled dietary intervention trials using effective low vs. high glucose response diets are necessary in order to draw more definite conclusions on the role of postprandial glycaemia in relation to health and disease. Also of importance is the evaluation of the potential role of the time course of postprandial glycaemia.

Original languageEnglish
Pages (from-to)923-984
Number of pages62
JournalObesity Reviews
Volume13
Issue number10
DOIs
Publication statusPublished - Oct 2012

Keywords

  • Health
  • physiological effects
  • postprandial glycaemia
  • risk factors
  • IMPAIRED GLUCOSE-TOLERANCE
  • GLUCAGON-LIKE PEPTIDE-1
  • CORONARY-HEART-DISEASE
  • TYPE-2 DIABETES-MELLITUS
  • BLOOD-BRAIN-BARRIER
  • DEPENDENT INSULINOTROPIC POLYPEPTIDE
  • GASTRIC-INHIBITORY POLYPEPTIDE
  • EXOGENOUS CARBOHYDRATE OXIDATION
  • CARDIOVASCULAR RISK-FACTORS
  • RANDOMIZED CONTROLLED-TRIAL

Cite this